Acuta Capital Partners’s IRulya Therapeutics IRLA Stock Holding History
Bought
Maintained
Sold
Other funds holding IRLA
SFCM
Acuta Capital Partners's IRLA Position: Q3 2026 in Review
Acuta Capital Partners opened a new position in IRulya Therapeutics (IRLA) in Q3 2026: 52,918 shares worth $1.64M. The stake represents 1.25% of the portfolio and ranks #23 among its holdings.
33 funds tracked by Wall St. Rank hold IRLA as of Q3 2026.
- Acuta Capital Partners held 52,918 shares of IRulya Therapeutics worth $1.64M as of Q3 2026.
- IRulya Therapeutics was a new Acuta Capital Partners position in Q3 2026.
- IRulya Therapeutics made up 1.25% of Acuta Capital Partners's portfolio in Q3 2026, its #23 holding.
- 33 funds tracked by Wall St. Rank held IRulya Therapeutics as of Q3 2026.
Based on Acuta Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.